

# Journal of the American Association for Pediatric Ophthalmology and Strabismus



ELSEVIER

## NEWS RELEASE FOR IMMEDIATE RELEASE

### Contacts:

Eileen Leahy

Elsevier

732 238 3628

[hmsmedia@elsevier.com](mailto:hmsmedia@elsevier.com)

Jennifer Hull

AAPOS

415-561-8505

[jhull@aao.org](mailto:jhull@aao.org)

---

## **Steroid Treatment in Very Low Birth Weight Infants May Contribute to Vision Problems**

**Modest but significantly increased risk of retinopathy in very premature infants is associated with steroid treatment, according to a new study published in the *Journal of AAPOS***

San Francisco, CA, August 16, 2016 – Because of the beneficial effect of corticosteroids on lung function, especially in infants who are ventilator dependent, corticosteroids are, at times, administered to very low birth weight neonates to treat established or evolving lung disease. However, it has long been suspected that steroids may have negative neurodevelopmental effects on very premature infants. In a study in the *Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)*, researchers found that for very premature infants with birth weights of less than 500 grams, there was a 1.6 times increased risk for retinopathy of prematurity (ROP) and a 1.7 times greater chance for advanced ROP.

Data on 1,472 neonates discharged from 167 Neonatal Intensive Care Units between 1996 and 2013 were collected from the Pediatrix BabySteps Clinical Data Warehouse, a large scale database of infant health records. Although this database contains information on more than 1.1 million infants, investigators restricted their analysis to extremely premature infants, with birthweights at the very lower limit of viability. These particular infants are at greatest risk for disorders associated with prematurity. Neonates in the study met three primary criteria: birth weight of less than 500 grams, discharged from hospital alive, and availability of ophthalmic ROP examination results. Diagnoses of ROP were standardized according to the International Classification of Retinopathy of Prematurity.

According to lead investigator Tammy Z. Movsas, MD, MPH, Medical Director, Midland County Department of Public Health, Midland, MI and Clinical Associate Professor of Pediatrics and Human Development, Michigan State University, School of Human Medicine, “Our study group consists of premature infants with birthweights at the lowest level that is compatible with life. This group represents a more homogeneous set of neonates than in other studies that consist of premature infants with a broader range of birthweights. Neonates at these critically low birth weights (and gestational ages) are at the absolute highest vulnerability

for a host of neonatal morbidities including ROP and bronchopulmonary dysplasia. Thus, clinical differences between steroid treated and untreated neonates are minimized.”

Results indicated that after correcting for lung disease as well as other factors that can contribute to ROP risk such as gestational age, there is still a higher risk of ROP in steroid-treated infants than in those infants not treated with steroids. 1,059 (72%) of the infants received postnatal steroids while 413 (28%) did not. The overall incidence of ROP (of any stage) for the entire group was 76.6%, and the overall incidence of advanced stage ROP (stages 3, 4, or 5) was 31.3%. The incidence of any ROP was significantly higher in steroid-treated infants (80.5%) than in nontreated infants (66.8%). For advanced stage ROP, incidence was also significantly higher in the treated group (35.3%) compared to the untreated group (21.1%).

“This study of a large database of critically low birth weight survivors indicates that steroid-treated infants have a modest but significantly increased risk for ROP. That said, clinicians need to use their best judgment to balance the positive effects from steroids on developing lungs with potential negative effects on developing eyes in very premature infants,” commented Dr. Movsas. This study has potential clinical significance since children with a history of ROP are not only at increased risk for visual impairments from the ROP itself, but are also at increased risk for developing other ocular disorders later in life.”

###

#### **NOTES FOR EDITORS**

“Postnatal corticosteroids and risk of retinopathy of prematurity,” by Tammy Z. Movsas, MD, MPH, Alan R. Spitzer, MD, and Ira H. Gewolb, MD, DOI: <http://dx.doi.org/10.1016/j.jaapos.2016.05.008>. It appears online ahead of the *Journal of AAPOS*, Volume 19, Issue 6 (December 2016) published by Elsevier.

Full text of the article is available to credentialed journalists upon request; contact Eileen Leahy at +1 732 238 3628 or [hmsmedia@elsevier.com](mailto:hmsmedia@elsevier.com) to obtain a copy. Journalists wishing to interview the authors should contact Dr. Tammy Z. Movsas at +1 989-430-7437 or [tmovsas@gmail.com](mailto:tmovsas@gmail.com).

#### **ABOUT THE JOURNAL OF AAPOS ([www.jaapos.org](http://www.jaapos.org))**

*Journal of AAPOS* presents expert information on children's eye diseases and on strabismus as it impacts all age groups. Major articles by leading experts in the field cover clinical and investigative studies, treatments, case reports, surgical techniques, descriptions of instrumentation, current concept reviews, and new diagnostic techniques. The *Journal* is the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

#### **ABOUT THE AMERICAN ASSOCIATION FOR PEDIATRIC OPHTHALMOLOGY AND STRABISMUS ([www.aapos.org](http://www.aapos.org))**

The goals of the AAPOS, the American Association for Pediatric Ophthalmology and Strabismus, are to advance the quality of children's eye care, support the training of pediatric ophthalmologists, support research activities in pediatric ophthalmology, and advance the care of adults with strabismus.

#### **ABOUT ELSEVIER**

Elsevier ([www.elsevier.com](http://www.elsevier.com)) is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions – among them ScienceDirect ([www.sciencedirect.com](http://www.sciencedirect.com)), Scopus ([www.scopus.com](http://www.scopus.com)), Elsevier Research Intelligence ([www.elsevier.com/research-intelligence](http://www.elsevier.com/research-intelligence)), and ClinicalKey ([www.clinicalkey.com](http://www.clinicalkey.com)) – and publishes over 2,500 journals, including *The Lancet* ([www.thelancet.com](http://www.thelancet.com)) and *Cell* ([www.cell.com](http://www.cell.com)), and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group ([www.relx.com](http://www.relx.com)), a world-leading provider of information and analytics for professional and business customers across industries. [www.elsevier.com](http://www.elsevier.com)